Interestingly, the use of small-molecule enhancement of autophagy through its clearance of metabolic waste has been suggested as a promising therapy in Alzheimer’s disease [30], consistent with the idea that drugs or small molecules targeting autophagy can act as a promising therapy in multiple conditions that are characterized by the overexpression of IL-1β. Here, IL1B is linked to early-onset autosomal dominant Alzheimer disease.